HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: Analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials

Journal of Pathology

Volumn 238, Issue 4, 2016, Pages 562-570

  Richman, Susan D ^a   Southward, Katie ^a   Chambers, Philip ^a   Cross, Debra ^b   Barrett, Jennifer ^a   Hemmings, Gemma ^a   Taylor, Morag ^a   Wood, Henry ^a   Hutchins, Gordon ^a   Foster, Joseph M ^c   Oumie, Assa ^c   Spink, Karen G ^c   Brown, Sarah R ^d   Jones, Marc ^d   Kerr, David ^e   Handley, Kelly ^f   Gray, Richard ^e   Seymour, Matthew ^a   Quirke, Philip ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c Thermo Fisher Scientific   (United States)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

amplification; colorectal cancer; HER2; overexpression, copy number variation

Indexed keywords

B RAF KINASE; CYCLOSPORIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONTROLLED STUDY; COPY NUMBER VARIATION; DIAGNOSTIC TEST ACCURACY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL; RECEPTOR UPREGULATION; TISSUE MICROARRAY; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); COLORECTAL TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MUTATION; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTOR, ERBB-2;

EID: 84959228461     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4679     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, et al., Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Wells A., EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-643.
3. Press MF, Bernstein L, Thomas PA, et al., HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15: 2894-2904.
4. Slamon DJ, Clark GM, Wong SG, et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
5. Slamon DJ, Godolphin W, Jones LA, et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
6. Leonard DS, Hill AD, Kelly L, et al., Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer. Br J Surg 2002; 89: 262-271.
7. Gravalos C, Jimeno A,. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-1529.
8. Bang YJ, Van Cutsem E, Feyereislova A, et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
9. Kavanagh DO, Chambers G, O'Grady L, et al., Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 2009; 9: 1.
10. Marx AH, Burandt EC, Choschzick M, et al., Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol 2010; 41: 1577-1585.
11. Ooi A, Takehana T, Li X, et al., Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004; 17: 895-904.
12. Osako T, Miyahara M, Uchino S, et al., Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998; 55: 548-555.
13. Sclafani F, Roy A, Cunningham D, et al., HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. Ann Oncol 2013; 24: 3123-3128.
14. Lee WS, Park YH, Lee JN, et al., Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. Cancer Med 2014; 3: 674-680.
15. Nathanson DR, Culliford ATt, Shia J, et al., HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 2003; 105: 796-802.
16. Caruso ML, Valentini AM,. Immunohistochemical p53 overexpression correlated to c-erbB-2 and cathepsin D proteins in colorectal cancer. Anticancer Res 1996; 16: 3813-3818.
17. Park SS, Kim SW,. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression. Oncol Rep 2007; 18: 139-143.
18. Quasar Collaborative G, Gray R, Barnwell J, et al., Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-2029.
19. Seymour MT, Maughan TS, Ledermann JA, et al., Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143-152.
20. Middleton G, Brown S, Lowe C, et al., A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan and Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). Eur J Cancer 2013; 49: 3507-3516.
21. Seymour MT, Brown SR, Middleton G, et al., Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013; 14: 749-759.
22. Hofmann M, Stoss O, Shi D, et al., Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805.
23. Richman SD, Seymour MT, Chambers P, et al., KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27: 5931-5937.
24. Douillard JY, Oliner KS, Siena S, et al., Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034.
25. Bertotti A, Migliardi G, Galimi F, et al., A molecularly annotated platform of patient-derived xenografts ('xenopatients') identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011; 1: 508-523.
26. Fasching PA, Weihbrecht S, Haeberle L, et al., HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics. Breast Cancer Res Treat 2014; 145: 193-203.
27. Fountzilas G, Christodoulou C, Bobos M, et al., Topoisomerase IIα gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. J Transl Med 2012; 10: 212.
28. Fountzilas G, Dafni U, Bobos M, et al., Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase IIα gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. BMC Cancer 2013; 13: 163.
29. Yonesaka K, Zejnullahu K, Okamoto I, et al., Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011; 3: 99ra86.
30. Martin V, Landi L, Molinari F, et al., HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer 2013; 108: 668-675.
31. Salvatore Siena AS-B, Lonardi S, Trusolino L, et al., Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): the HERACLES trial. J Clin Oncol 2015; 33 (suppl); abstr 3508.
32. Valtorta E, Martino C, Sartore-Bianchi A, et al., Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol 2015; 28: 1481-1491.
33. Kloth M, Ruesseler V, Engel C, et al., Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. Gut 2015; DOI: 10.1136/gutjnl-2014-309026.
34. Kavuri SM, Jain N, Galimi F, et al., HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov 2015; 5: 832-841.
35. Bertotti A, Papp E, Jones S, et al., The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015; 526: 263-267.